Dissociation of glucagon's central and peripheral hemodynamic effects: Mechanisms of reduction and redistribution of canine hindlimb blood flow by Kazmers, Andris et al.
JOURNAL OF SURGICAL RESEARCH M,384-390 (1981) 
Dissociation of Glucagon’s Central and Peripheral Hemodynamic 
Effects: Mechanisms of Reduction and Redistribution of 
Canine Hindlimb Blood Flow 
ANDRE KAZMERS, M.D., WALTER M. WHITEHOUSE, JR., M.D., 
S. MARTIN LINDENAUER, M.D., AND JAMES C. STANLEY, M.D. 
Division of Peripheral Vascular Surgery, Department of Surgery, University of Michigan Medical School, 
Ann Arbor, Michigan 48109 
Presented at the Annual Meeting of the Association for Academic Surgery, Birmingham, Alabama, 
November 5-8, 1980 
Effects of parenterally administered pharmacologic doses of glucagon on canine hindlimb 
blood flow were studied. Cardiac output (CO), mean arterial pressure (MAP), total peripheral 
resistance (TPR), common femoral artery flow (CFAQ), common femoral artery resistance 
(CFAR), percentage shunt in the hindlimb (AVA%) determined by 99mTc microsphere technique, 
the volume of hindlimb shunt flow (AVAQ), and the volume of hindlimb nutrient capillary flow 
(NCQ) were determined at baseline and at 10, 20, and 30 min during continuous intravenous 
infusion of 1 &kg/min glucagon (n = 8). Blood glucagon and glucose levels were measured 
at all time periods. Glucagon infusion significantly increased CO throughout the infusion, while 
reducing MAP and TPR. Unexpectedly, CFAQ decreased significantly despite the increase in 
CO. CFAR increased despite the reduction of TPR during glucagon infusion. The reduction of 
CFAQ was associated with diminished nonshunt hindlimb NCQ and increased AVA%. Changes 
in CFAQ, AVA%, AVAQ, and NCQ did not correlate in a linear fashion with the changes in 
either blood glucose or glucagon levels by linear regression analysis. Glucagon appeared to cause 
a major redistribution of peripheral blood flow. Hindlimb arteriolar dilatation was not an effect 
of this hormone in this experimental model. Glucagon appeared to have a salutary central hemo- 
dynamic effect, but was detrimental to canine extremity perfusion. 
Microcirculatory effects of pharmacologic 
doses of glucagon were examined in the 
canine hindlimb. The physiologic effects of 
this agent on central and splanchnic hemo- 
dynamics have been examined extensively, 
yet few studies have addressed the ef- 
fects of glucagon on extremity blood flow. 
The objective of this study was to deter- 
mine the manner by which parenterally ad- 
ministered glucagon altered canine extremity 
circulation through naturally occurring pre- 
capillary hindlimb arteriovenous anastomo- 
ses (AVA) and through the remaining capil- 
lary network. Alterations in microcircula- 
tory hindlimb hemodynamics were evaluated 
in relation to changes in systemic hemo- 
dynamics, plasma glucose, and plasma glu- 
cagon levels during continuous intravenous 
infusion of this hormone. 
MATERIALS AND METHODS 
Eight fasted adult dogs with a mean 
weight of 27 kg (23-34 kg) were anes- 
thetized with 30 mg/kg pentobarbital ad- 
ministered intravenously. Supplemental pen- 
tobarbital (5 mg/kg) was used as needed, 
but experimental manipulations were not 
performed until 40 min following drug ad- 
ministration. 
Animals were intubated and mechanically 
ventilated, maintaining arterial blood gases 
within physiologic range. Subjects with acid- 
base disturbances or hypoxia were not 
studied. Core temperature was carefully 
monitored, and all subjects remained nor- 
mothermic throughout the experiment. The 
dogs received a 20 cc/kg bolus of lactated 
Ringer’s solution prior to glucagon ad- 
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ministration and a 10 cc/kg/min continuous 
infusion throughout the study. 
Carotid arterial and centrally threaded 
jugular venous catheters were positioned 
for measurement of systemic arterial and 
central venous pressure using strain gauge 
pressure transducers. These data and heart 
rates were continuously documented using 
a multichannel recorder. A 7-french ther- 
modilution Swan-Ganz catheter was posi- 
tioned with its tip in the pulmonary artery, 
and the mean pulmonary capillary wedge 
pressure (PCWP) was determined inter- 
mittently during the study. Cardiac output 
was measured in triplicate at each experi- 
mental period using the thermodilution 
principle. Total peripheral vascular resist- 
ance (TPR), in dyn-sec/cm5, was calculated 
using the formula 
TPR = 
mean arterial pressure (MAP) - central venous pressure 
x 79.9. 
cardiac output 
Left ventricular stroke work (LVSW) was 
approximated by the formula 
Lvsw = (MAP - PCWW 
Heart Rate 
x cardiac output. 
An estimation of external cardiac work 
(ECW) was calculated at each interval by 
the formula: ECW = MAP x CO. 
A precalibrated nonoccluding square 
wave electromagnetic flow probe was 
placed on the common femoral artery for 
measurement of total common femoral 
artery flow (CFAQ). Vascular resistance in 
the common femoral artery (CFR) in dyn- 
sec/cm5, was calculated disregarding fem- 





A 22-gauge catheter was positioned with 
its tip at the common femoral artery bi- 
furcation for injection of sg”Tc-labeled al- 
bumin microspheres. These spheres were 
20 pm in mean diameter, ranging in size 
from 10 to 35 pm, with only 5% of spheres 
outside these limits. Spheres were freshly 
prepared and were discarded if any ab- 
normality in size existed, or if greater than 
1% unlabeled radioactivity was detected by 
instant thin-layer chromatography. Spheres 
were sonicated prior to withdrawal into a 
l-cc microsyringe and again prior to injection. 
The actual radioactivity of the injectate 
was determined by measuring the energy 
of the syringe in a radioisotope dose cali- 
brator both before and after injection. Times 
of injection, as well as initial and final 
calibrations, were noted, and the amount 
injected was corrected for the expected 
radioactive decay. Residual radioactivity 
in injection catheters was exceedingly small 
and was disregarded in subsequent calcula- 
tions. A nuclear scanner calibrated for 
measurement of ggmTc, with a 12.7-cm 
detector with a straight-bore collimator 
was placed in a fixed position over the 
right upper thorax. Microspheres of the 
size used in this study, when injected into 
the common femoral artery, are predictably 
trapped in the hindlimb microcirculation 
unless they pass through arteriovenous 
anastomoses [ 121. Shunted microspheres 
passing from the arterial to the venous cir- 
culation are predictably trapped in the 
lung, where their presence is detectable 
as an increase in radioactivity [2, 12, 18, 
231. The efficacy of the lung as a micro- 
sphere trap has been well established 
[3, 9, 191. A femoral venous injection of a 
known dose of microspheres was used as a 
“ 100% reference shunt” to establish the 
change in counts per minute (Acpm) over 
the chest for total shunting (as determined 
in triplicate by the scanner’s digital scaler) 
per microcurie injected. From 25,000 to 
37,500 microspheres were injected at each 
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time period in a volume of 10.1 cc. Spheres 
were injected upstream such that CFQ was 
not disturbed. The percentage shunt within 
the common femoral artery circulation was 
calculated by a standard formula for each 
intraarterial microsphere injection [2, 121. 
% Shunt 
Acpm over chest after arterial injection 
dose of arterial injection = 
Acpm over chest after venous injection 
dose of venous injection 
x 100. 
The actual volume of shunt flow that by- 
passed the hindlimb capillary network was 
determined by the formula: hindlimb shunt 
flow = % shunt x total common femoral 
artery flow [2,23]. Nonshunt hindlimb blood 
flow, which was presumably of a nutritive 
nature, was calculated by subtracting the 
volume of shunt flow from total common 
femoral artery flow 12, 231. 
The following data were obtained after 
having achieved a stable baseline: cardiac 
output, mean arterial pressure, central 
venous pressure, total peripheral vascular 
resistance, pulmonary capillary wedge pres- 
sure, left ventricular stroke work, heart 
rate, external cardiac work, total common 
femoral artery flow, common femoral vas- 
cular resistance, percentage hindlimb shunt, 
as well as the volume of hindlimb shunt 
flow, and volume of nonshunt nutrient 
capillary blood flow. Measurements were 
repeated at 10, 20, and 30 min during 
continuous peripheral intravenous infusion 
of 1 &kglmin glucagon. Blood glucose 
levels (hexokinase method), and plasma 
glucagon levels (radioimmunoassay) were 
also determined at these time intervals 
[ 161. Data were analyzed by paired c and 
Wilcoxon signed-rank tests. Correlation 
matrices were performed and Pearson prod- 
uct-moment correlation coefficients de- 
termined. Linear regression analysis was 
performed in standard fashion using the 
least squares method. 
RESULTS 
Central Effects 
Cardiac output rose significantly, and 
elevations persisted throughout glucagon 
infusion (Table 1). Both mean arterial pres- 
sure and total peripheral vascular resistance 
fell as cardiac output increased. Mean 
arterial pressure and total peripheral vas- 
cular resistance correlated in a linear fash- 
ion at 10, 20, and 30 min (P < 0.05). Left 
ventricular stroke work decreased sig- 
nificantly, and heart rate rose significantly 
during glucagon infusion. Cardiac output 
increases during drug infusion did not cor- 
relate significantly with increased heart 
rates. Despite decreases in left ventricular 
stroke work, external cardiac work did not 
change significantly from baseline during 
drug infusion, but tended to increase at 10 
and 30 min (0.05 < P < 0.1). 
Peripheral Effects 
Despite increases in cardiac output, total 
common femoral artery flow decreased 
throughout drug infusion (Table 2). Further- 
more, despite decreases in total peripheral 
vascular resistance, resistance in the com- 
mon femoral artery circulation increased 
significantly at 10 and 20 min. The dis- 
sociation of cardiac output and femoral 
flow, as well as the dissociation of total 
peripheral and hindlimb vascular resistance, 
were unanticipated findings. Femoral artery 
flow and resistance correlated inversely 
and significantly throughout the drug in- 
fusion (P < 0.05). 
In addition to reducing total common 
femoral artery blood flow, glucagon infusion 
produced a significant redistribution of 
hindlimb blood flow (Table 2). Percentage 
hindlimb shunt rose significantly from a 
baseline value of 10.5 + 6.5% and was ap- 
proximately doubled to a value of 20.7 
2 12.5% at 30 min of drug infusion. The 
volume of hindlimb shunt flow increased, 
but the change in absolute shunt flow was 
not statistically significant by Wilcoxon 
signed-rank tests, though the change ap- 
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TABLE 1 
CENTRAL EFFECTS 
Glucagon infusion periods 
Baseline 10 min 20 min 30 min 
Cardiac output (Ymin) 
Mean arterial pressure 
(mm Hg) 
Total peripheral resistance 
(dyn-sec/cm5) 
Left ventricular stroke work 
External cardiac work 
Heart rate 
4.15 * 0.37 5.33 k 0.63** 5.15 t 0.38*** 5.23 f 0.35** 
124 + 23 109 k 19*** 104 -c 17** 105 2 19** 
2440 k 490 1686 k 321** 1653 5 283** 1660 f 395** 
3.01 f 0.37 2.71 2 0.47 (ns) 2.40 + 0.18** 2.50 f 0.24* 
514 k 114 584 t 132 (ns) 534 2 106 (ns) 544 k 88 (ns) 
166 -c 36 212 ? 38** 219 -r- 41*** 215 ? 39*** 
Note. Data assessed for statistical significance in comparison to baseline values (n = 8) using paired t test. 
Measurements expressed as x ? 1 SD. 
* P < 0.05. 
** P -=c 0.01. 
***p < 0.001. 
ns, not significant. 
proached significance at 10 and 30 min Assuming shunt flow to be normally dis- 
(0.05 < P < 0.10). tributed, the increase in shunt flow was sig- 
The lack of significant change in ab- nificant by a two-tailed paired r test at 10 
solute shunt flow reflected the fact that total min (P < 0.05). Shunt flow was inversely 
femoral artery flow was decreased as per- related to common femoral artery resist- 
centage of hindlimb shunt was increased. ante at 10 and 20 min (P < 0.05). While 
TABLE 2 
PERIPHERAL EFFECTS 
Glucagon infusion periods 
Baseline 10 min 20 min 30 min 
Common femoral blood flow 
(ml/min) 146 ? 33 108 + 31*** 110 ? 29** 114 * 311 
Common femoral resistance 
(dyn-sec/cm6) 70,181 f 17,583 86,977 + 28,156* 79,805 2 22,532* 77,585 5 21,758 (ns) 
Percentage common femoral 
artery shunt 10.5 2 6.5 18.2 2 8.2* 19.6 ? 10.3* 20.7 L 12.5** 
Common femoral artery 
shunt flow (ml/min) 15.3 2 10.5 20.7 + 12.1* 22.3 t- 13.4 (ns) 24.6 2 19.4 (ns) 
Common femoral artery 
nutrient capillary flow 
(ml/mitt) 131 -t 31 88.6 f 23** 88.3 + 25** 89.8 -t 26* 
Nofe. Data assessed for statistical significance in comparison to baseline values (n = 8) using paired t and 
Wilcoxon signed-rank tests. Measurements expressed as d + 1 SD. 
*P < 0.05. 
** P < 0.01. 
*** P < 0.001. 
ns, not significant. 
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percentage shunt and absolute shunt flow 
were increasing, nutrient capillary hindlimb 
blood flow decreased significantly, and this 
occurred despite the improvement in cardiac 
output during glucagon infusion. Nutrient 
capillary flow appeared inversely related to 
common femoral artery resistance at 10,20, 
and 30 min (P < 0.05). The changes in total 
common femoral artery flow, percentage 
shunt, absolute shunt flow, and hindlimb 
capillary flow did not correlate in a linear 
fashion with either changes in glucose or 
glucagon levels. Other hemodynamic param- 
eters measured in this study did not cor- 
relate in a consistent or meaningful way 
with blood glucagon levels with two ex- 
ceptions. At 10 min, glucagon levels cor- 
related with heart rate (P < 0.05; I = 0.82). 
At 20 min, glucagon levels correlated in- 
versely with total peripheral vascular re- 
sistance (P < 0.05; r = -0.72). 
Blood glucose and glucagon levels were 
both altered significantly during the study. 
Glucose increased from a baseline level of 
96 -t 18 mg/dl to 183 2 26, 202 & 30, and 
208 + 41 mg/dl at 10, 20, and 30 min, 
respectively (P < 0.001). Glucagon levels 
also increased significantly from baseline 
values of 213 2 148 pg/ml to 836 f 52, 
954 ? 77, and 939 -c-131 pg/ml at 10, 20, 
and 30 min, respectively (P < 0.001). 
DlSCUSSlON 
Glucagon in pharmacologic doses is known 
to increase cardiac output, decrease total 
peripheral resistance, and increase splanch- 
nit blood flow [5, 10, 13, 15, 201. The 
effect of glucagon on extremity blood 
flow has not been as clearly defined. Pre- 
vious experiments have found little effect 
of parenteral glucagon infusion on ex- 
tremity perfusion in normal human sub- 
jects and in a feline experimental model 
[ 1, 4, 201. Other investigators reported 
that parenteral glucagon administration sig- 
nificantly reduced hindlimb blood flow in 
the dog [6, 10, 11, 131. To add to the con- 
fusion, it had also been reported that 
direct infusion of glucagon into an isolated 
perfused canine hindlimb preparation re- 
sulted in decreased hindlimb vascular resist- 
ance [5]. In the latter study the number 
of dogs was very small, drug doses were 
high, and no statistical analysis of the data 
was provided for evaluation. Interestingly, 
direct infusion of glucagon into the feline 
femoral artery did not alter femoral flow 
but did result in increased splanchnic 
blood flow [20]. 
Hemodynamic alterations induced by a 
vasoactive agent in one regional vascular 
bed do not necessarily reflect the effects 
of the drug on systemic hemodynamics. 
For example, in another study from our 
laboratory, 1 pg/kg/min glucagon infusion 
administered by peripheral vein markedly 
increased superior mesenteric artery (SMA) 
blood tlow and lowered SMA vascular re- 
sistance. In this experiment SMA blood 
flow comprised a significantly greater pro- 
portion of cardiac output during drug in- 
fusion indicating that glucagon acted as a 
selective mesenteric arterial dilator. The ef- 
fects within the SMA microcirculation were 
also markedly different than those in the 
canine hindlimb. Percentage hindlimb shunt 
was high at baseline, 10.5 & 6.5%, and 
increased significantly during glucagon in- 
fusion. In contrast, baseline canine SMA 
% shunt was low, 1.79 -+ 0.94%, and did 
not change significantly during glucagon in- 
fusion. Nonshunt capillary flow increased 
markedly in the gut, but decreased sig- 
nificantly in the hindlimb. It may be postu- 
lated that glucagon exerts a specific micro- 
circulatory effect in the canine hindlimb 
which cannot be explained by simple arteri- 
olar dilatation or constriction. It appears 
canine hindlimb AVA can respond dif- 
ferently than arterioles when subjected to 
vasoactive agents, and perhaps are reg- 
ulated independently of arterioles and capil- 
laries [23]. 
Reduction in total peripheral resistance 
and mean arterial pressure with adminis- 
tration of glucagon has been well docu- 
mented, and is the result of vasodilation 
in regional beds other than the hindlimb 
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[lo, 131. The increase in cardiac output 
was not dependent solely on heart rate, and 
did not correlate with the increase in heart 
rate during glucagon administration in our 
study. Other studies have shown that 
inotropic effects persist despite myocardial 
pacing, and therefore are not dependent 
on the positive chronotropic effect of 
glucagon [5]. The effect of glucagon in 
lowering left ventricular stroke work must 
be tempered with the fact that heart rate 
can increase significantly. This renders 
the effect of glucagon on myocardial ener- 
getics unpredictable, as indicated by the 
tendency for external cardiac work to in- 
crease in our study. 
The deleterious effect of pharmacologic 
doses of glucagon in the extremity cir- 
culation may be mediated by the sympathetic 
nervous system [l 11. Glucagon is known to 
cause release of epinephrine and nonepi- 
nephrine from the adrenal medulla [2 1, 221. 
Although experimental administration of 
catecholamines concomitantly with glucagon 
does not prevent splanchnic vasodilatation, 
it is possible that the hindlimb remains 
responsive to such catecholamines [ 111. 
However, the current study tends to refute 
such a postulate. The usual response of 
the canine hindlimb to catecholamines is 
decreased shunt and nutrient flow [23]. Our 
study documented an increase in AVA 
shunting that would not be a likely effect 
of increased sympathoadrenal activity. Thus, 
the results of this experiment cannot be 
explained simply by a glucagon-induced 
catecholamine effect on the hindlimb micro- 
circulation. 
The implications of this study are two- 
fold. First, beneficial central hemodynamic 
effects of glucagon may not be paralleled 
by similar effects in the extremity circula- 
tion. Second, previous canine metabolic 
studies examining arteriovenous differences 
and uptake of various substrates such as 
glucose or amino acids with glucagon ad- 
ministration should be subject to reexamina- 
tion. Arteriovenous shunting was never 
considered in these experiments. For ex- 
ample, the conclusion that glucagon causes 
decreased peripheral utilization of glucose, 
with a high venous glucose concentration 
and narrow arteriovenous glucose differ- 
ence across the canine hindlimb, might be 
the result of hindlimb AVA shunting and 
not a reflection of the true metabolic role 
of glucagon. 
The dissociation of hindlimb shunt and 
nutrient capillary blood flow is postulated 
to be the result of a specific microcir- 
culatory effect of glucagon. The changes 
in hindlimb hemodynamics are not related 
in a linear fashion to blood glucose or 
glucagon levels. It appears the speculation 
that glucagon might cause arteriovenous 
shunting is true at least for the canine 
hindlimb regional vascular bed [7,8, 14, 171. 
The peculiar effects of pharmacologic doses 
of glucagon on canine hindlimb hemody- 
namics are so dissimilar to the effects of 
the drug on systemic hemodynamics, that 
conclusions regarding hindlimb microcir- 
culatory effects are not predictive of the 
effects on central hemodynamics and should 
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